Coherus Oncology, Inc. CHRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
4/9
Piotroski F — financial health
-20.15
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $42.2M | $168.0M | — | — | $61.0M |
| 2024 | $26.4M | $28.5M | — | — | -$132.0M |
| 2023 | $257.2M | -$237.9M | — | -$175.2M | -$193.4M |
| 2022 | $211.0M | -$291.8M | — | -$243.2M | -$137.4M |
| 2021 | $326.6M | -$287.1M | — | -$38.7M | $97.7M |
| 2020 | $475.8M | $132.2M | — | $146.9M | $281.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Satvat Ali J. | director | 2026-06-05 | Grant | 30,000 | — |
| Karachun Rita A | director | 2026-06-05 | Grant | 30,000 | — |
| Newcomer Lee Nisley | director | 2026-06-05 | Grant | 30,000 | — |
| Ryan Michael Lee | director | 2026-06-05 | Grant | 30,000 | — |
| O'Donnell-Tormey Jill | director | 2026-06-05 | Grant | 30,000 | — |
| Wahlstrom Mats | director | 2026-06-05 | Grant | 30,000 | — |
| Newton Charles W. | director | 2026-06-05 | Grant | 30,000 | — |
| Lanfear Dennis M | President & CEO | 2026-01-23 | Grant | 375,000 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -20.15 (distress)
- Working capital / assets 0.257
- Retained earnings / assets -5.353
- EBIT / assets -0.701
- Equity / liabilities 0.309
Source: SEC EDGAR filings · CIK 0001512762 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.